<DOC>
	<DOCNO>NCT00796029</DOCNO>
	<brief_summary>The purpose study investigate metabolic pathway paliperidone excretion paliperidone metabolites healthy adult male volunteer , CYP2D6 poor extensive metabolizers , administration single 1-mg oral dose 14C-paliperidone , evaluate safety tolerability paliperidone , determine relationship genotype ( CYP2D6 , CYP3A4 , CYP3A5 , UGT1A1 , UGT1A6 ) exposure paliperidone metabolite .</brief_summary>
	<brief_title>A Study Plasma Concentrations , Metabolism Excretion 14C-paliperidone After Single Oral Dose</brief_title>
	<detailed_description>This study design single-center , single-dose , open-label study absorption , metabolism , excretion paliperidone healthy men ( 3 extensive 3 poor metabolizers base CYP2D6 phenotype ) . Eligible volunteer admit study center even study drug administration remain study center 168 hour dose ( longer require maximum 14 day ) . Each volunteer receive single oral dose 14C-paliperidone total radioactivity 1000 µSv ( 16 mCi ) . Blood sample plasma pharmacokinetic profile obtain immediately study drug administration 0.5 , 1 , 1.5 , 3 , 6 , 12 , 16 , 36 , 48 , 72 , 96 , 120 , 144 168 hour postdose . Blood sample obtain 2 , 4 , 8 24 hour postdose determination 14C whole blood . Samples determination serum creatinine obtain 2 , 4 , 8 24 hour postdose . Urine collect immediately prior drug administration 0-4 , 4-8 , 8-12 , 12-16 , 16-24 , 24-36 , 36-48 , 48-72 , 72-96 , 96-120 , 120-144 , 144-168 hour study drug administration . Fecal sample collect per stool , study drug administration period 0-168 hour study drug administration . Collections urine feces ( per 24 hour ) continue beyond 168 hour , maximum 336 hour ( Day 15 ) patient excrete radioactivity slowly ( 2 late 24-hour urine collection great equal 2 % total radioactive dose ) &lt; 7 feces stool sample 0 168-hour period . 14C radioactivity measure plasma , urine , feces . Aliquots 0- 24 hour urine collection analyze creatinine . Plasma concentration paliperidone risperidone determine mean validate LC MS/MS method . The 14C-labeled moiety plasma urine determine liquid scintillation counting . For plasma sample , low limit quantification paliperidone risperidone 0.100 ng/mL . For plasma urine sample low limit quantification 14C-paliperidone 72 dpm/mL ( =2.0n g eq/mL ) . The rationale present study single-dose administration 1 mg 14C-paliperidone healthy white men determine route excretion paliperidone elucidate metabolic pathways structure predominant paliperidone metabolite . As , study result complete understanding pharmacokinetics paliperidone human . Safety tolerability monitor . Volunteers receive single oral 1 mg dose 14C-paliperidone solution specific activity 592 kBq/mg , result administer radioactivity 592 kBq ( 16 µCi ) . The total radioactive load subject remain low 1000 µSv .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Dextromethorphan metabolic ratio &gt; 0.345 ( poor metabolizer ) &lt; 0.0255 ( extensive metabolizer ) Body Mass Index : ( weight [ kg ] /height [ ] 2 ) 20 28 kg/m2 , inclusive Volunteers must sign informed consent document indicate understand purpose procedure require study willing participate study Healthy base prestudy physical examination , medical history , ECG , result hematology serum chemistry test , urinalysis carry within 3 week prior administration study drug . If result hematology test , serum chemistry test ( except liver enzymes serum creatinine ) , urinalysis within laboratory 's reference range , volunteer include condition investigator judge deviation clinically significant . Relevant history cardiac arrhythmia , bronchospastic cardiovascular disease ( e.g. , history ischemic heart disease cerebrovascular accident ) respiratory , neuropsychiatric , renal , hepatic , gastrointestinal ( include surgery , malabsorption problem ) , endocrine ( include diabetes mellitus thyrotoxicosis ) , immunologic disease parkinsonism drug allergy History cancer , exception basal cell carcinoma Have receive experimental drug use experimental medical device within 30 day plan start treatment History smoking use nicotinecontaining substance within last 2 month , determine medical history and/or volunteer 's verbal report History alcohol substance abuse . Positive test result urine drug screen alcohol breath test upon admission study center Day 1 Positive result serology test ( hepatitis B surface antigen , human immunodeficiency virus [ HIV ] antibody , hepatitis C viral antibody ) Liver function test serum creatinine exceed normal limit screen</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Antipsychotic drug : 14C-paliperidone</keyword>
</DOC>